Ізраїль - іврит - Ministry of Health

bayer israel ltd - cyproterone acetate - טבליה - cyproterone acetate 50 mg - cyproterone - cyproterone - for antiandrogen therapy in men: sexual disorders, inoperable prostatic carcinoma.

Ізраїль - іврит - Ministry of Health

sanofi israel ltd - metronidazole as benzoate - תרחיף - metronidazole as benzoate 25 mg/ml - metronidazole - metronidazole - infections caused by anaerobic bacterias, amebiosis, lambliasis and trichomonas.

Ізраїль - іврит - Ministry of Health

sanofi israel ltd - metronidazole - טבליות מצופות פילם - metronidazole 250 mg - metronidazole - metronidazole - trichomonias, acute intestinal amebiasis. infections due to anaerobic bacteria.

Ізраїль - іврит - Ministry of Health

astra zeneca (israel) ltd - fulvestrant - תמיסה להזרקה - fulvestrant 250 mg / 5 ml - fulvestrant - fulvestrant - faslodex is indicated for the treatment of postmenopausal women with oestrogen receptor positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant antioestrogen therapy or disease progression on therapy with an antioestrogen.

Ізраїль - іврит - Ministry of Health

astra zeneca (israel) ltd - fulvestrant - תמיסה להזרקה - fulvestrant 250 mg / 5 ml - fulvestrant - fulvestrant - faslodex is indicated for the treatment of postmenopausal women with oestrogen receptor positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant antioestrogen therapy or disease progression on therapy with an antioestrogen.06/06/2010 בקשה לשינוי משטר מינון the recommended dose is 500 mg at intervals of one month, with an additional 500 mg dose given two weeks after the initial dose.

Ізраїль - іврит - Ministry of Health

astrazeneca (israel) ltd - fulvestrant - תמיסה להזרקה - fulvestrant 250 mg / 5 ml - fulvestrant - fulvestrant - faslodex is indicated for the treatment of postmenopausal women with oestrogen receptor positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant antioestrogen therapy or disease progression on therapy with an antioestrogen.

Ізраїль - іврит - Ministry of Health

dexcel pharma technologies ltd - levetiracetam - טבליה - levetiracetam 250 mg - levetiracetam - levetiracetam - levetiracetam dexcel is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.levetiracetam dexcel is indicated as adjunctive therapy:• in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy.• in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy.• in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

Ізраїль - іврит - Ministry of Health

dexcel pharma technologies ltd - levetiracetam - טבליה - levetiracetam 500 mg - levetiracetam - levetiracetam - levetiracetam dexcel is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.levetiracetam dexcel is indicated as adjunctive therapy:• in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy.• in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy.• in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

Ізраїль - іврит - Ministry of Health

dexcel pharma technologies ltd - levetiracetam - טבליה - levetiracetam 1000 mg - levetiracetam - levetiracetam - levetiracetam dexcel is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.levetiracetam dexcel is indicated as adjunctive therapy:• in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy.• in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy.• in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

Ізраїль - іврит - Ministry of Health

takeda israel ltd - lanthanum as carbonate hydrate - טבליות לעיסות - lanthanum as carbonate hydrate 500 mg - lanthanum carbonate - lanthanum carbonate - fosrenol is indicated as a phosphate binding agent for use in the control of hyperphosphatemia in crf patients on haemodyalisis or continuous ambulatory peritoneal dialysis (capd).fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels > or = 1.78 mmol/l in whom a low phosphate diet alone is insufficient to control serum phosphate levels.